GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world’s first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer. The Hyperfine system is 20X lower cost, 35X lower power consumption, and 10X lower weight than today’s fixed conventional MRI systems.
“Nearly six years ago, a dream to create a portable, affordable MRI system was born. We assembled an astounding team, and they took the 10 million-fold improvement in computing power since MRI was invented and the best of the billions invested in green electronics and built something astonishing, something disruptive,” said Jonathan Rothberg, PhD, founder and chairman of Hyperfine Research.
The Hyperfine point-of-care device represents multiple innovations in MRI design, architecture and workflow; more than 100 patents have been issued or are currently pending. The system is highly portable and wheels directly to the patient’s bedside, plugs into a standard electrical wall outlet, and is controlled via a wireless tablet such as an Apple iPad®.
The Hyperfine system was designed to address the limitations of current MRI systems in order to make MRI accessible anytime, anywhere, to any patient. “More than 40 years after its first use, MRI remains a marvel. Unfortunately, it also remains inaccessible. It’s time that MRI made the jump to point of need just like X-ray and ultrasound have before it,” said Dr. Khan Siddiqui, Hyperfine’s Chief Medical Officer. “Going beyond that, nearly 90% of the world has no access to MRI at all. With the FDA’s decision, we are now ready to rewrite the rules of MRI accessibility.”
In developing the system, Hyperfine performed thousands of brain scans including those within investigational partnerships at Yale New Haven University, Penn Medicine, Good Samaritan Hospital Long Island, New York Presbyterian Brooklyn Methodist Hospital, and Brown University, in addition to calling upon seminal work from the Martinos Center for Biomedical Imaging at Massachusetts General Hospital. The FDA clearance includes head imaging for patients 2 years of age and older. Hyperfine is now accepting product pre-orders via www.hyperfine.io
MRI uses a magnetic field, radio waves and a computer to produce detailed pictures of the body's internal structures that are clearer, more detailed and more likely in some instances to identify and accurately characterize disease than other imaging methods.
Learn more: www.hyperfine.io
Upcoming Conference Participation
Hyperfine will be demonstrating the system at the International Stroke Conference, Los Angeles, CA February 19-21; NVIDIA GPU Technology Conference, San Jose, CA March 23-26; and, the American Society of Neuroradiology, Las Vegas, NV May 30 – June 4, 2020.
Founded by Jonathan Rothberg, PhD in 2014, Hyperfine is part of the 4Catalyzer family of companies. 4Catalyzer is a health technology incubator with facilities in Connecticut, New York City, Palo Alto, and Taiwan. Hyperfine is on a mission to make MRI accessible to every patient regardless of income or resources, anywhere, anytime. www.hyperfine.io.